Bridge Pharmaceuticals is a US-based SRI International (formally Stanford Research Institute) spin-off company focused on providing lower cost, FDA compliant drug development services in Asia for US and EU based clients. We use an exclusive network of pre-qualified flagship Asian laboratories with validated SOP's and QA audits. This, together with Bridge technical, quality assurance and regulatory staff directly managing the studies in the US and on the ground in Asia, leaves nothing to chance.
